Current Mounjaro Prices UK - Use FIRST40 Discount Code
Save £40 with Code FIRST40 - Apply Before Price Increases
Get immediate £40 savings on your first Mounjaro order with exclusive discount code FIRST40. Simply enter at checkout for instant discount on all strengths. With ongoing price pressures across UK pharmacies, secure your prescription-only tirzepatide at current rates.
First Order Mounjaro Prices with FIRST40 Code
2.5mg starter pen: £129.99 (was £169.99) - save £40 instantly. 5mg pen: £159.99 (was £199.99). 7.5mg pen: £209.99 (was £249.99). 10mg pen: £229.99 (was £269.99). 12.5mg pen: £259.99 (was £299.99). 15mg pen: £278.99 (was £318.99). Order now with FIRST40 code before next price adjustment.
Multi-Pen Bundle Savings with FIRST40 Discount
Intro Duo Bundle (2.5mg + 5mg): £299.99 first order - total saving of £80 versus individual purchases. Progress Duo (5mg + 7.5mg): £369.99 first order. Advance Duo (7.5mg + 10mg): £449.99 first order. Three-pen Intro Trio: £534.99 first order. Apply FIRST40 at checkout for automatic discount on all bundles.
How to Apply Your FIRST40 Discount Code
Step 1: Select your Mounjaro strength or bundle. Step 2: Complete online clinical assessment. Step 3: Enter discount code FIRST40 at checkout. Step 4: Pay discounted price - £40 off applied automatically. Code valid on all prescription-only Mounjaro products once clinical approval confirmed.
Express Approval Available - Get Mounjaro Faster
Standard approval: 3 working days with clinical assessment. Express upgrade: 24-hour approval available for urgent orders. Beat potential supply delays with express processing. Our GPhC-registered clinicians review all assessments for prescription-only tirzepatide supply. Order today with FIRST40 code for immediate savings.
Why Order Mounjaro Now with FIRST40 Code
Lock in current pricing before next increase across UK market. Genuine prescription-only tirzepatide from MHRA-licensed suppliers. This once-weekly injectable activates GIP and GLP-1 hormones, may help regulate appetite and promote feeling of fullness alongside reduced-calorie diet and increased physical activity. Subject to MHRA additional monitoring with comprehensive patient support.
